These responses included dimension reductions in both primary tumors and mediastinal lymph nodes, suggesting tumor down-staging. Therefore, it is intriguing

to consider the utilization of targeted therapies as an adjunct to make VS-4718 in vivo the “”unresectable”" become resectable. Neoadjuvant target therapy for NSCLC could potentially become a new treatment option for locally advanced and metastatic disease. On the other hand, we should not ignore the possibility that gene mutation status of primary tumors is different from that of their metastases when neoadjuvant target therapy is considered. If discordance between primary tumors and metastases is not evaluated before therapy, the patients may not benefit from the targeted therapies. Taken together, we propose that biopsies of both primary tumors and metastatic tumors of patients with advanced NSCLC, though difficult to obtain, should be pursued to ascertain AUY-922 order the mutation status of key genes. This will allow clinicians

to better understand gene mutation status and the biology of patient tumors, so that better treatment options can be selected based on tumor responsiveness to those available targeted therapies such as EGFR TKI. Conclusions In summary, the substantial discordance of KRAS and EGFR mutation status between primary tumors and metastatic tumors may have therapeutic implications for EGFR-targeted therapy strategy. For NSCLC patients with metastases, determining the KRAS and EGFR mutation status in both primary and metastatic tumors may be critical for making meaningful decisions regarding the appropriate use of targeted therapies. References 1. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA: Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008, 83:584–594.PubMedCrossRef 2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Tideglusib in vivo Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225–249.PubMedCrossRef

3. Hansen HH: Treatment of advanced non-small cell lung cancer. BMJ 2002, 325:452–453.PubMedCrossRef 4. Hirsch FR, Varella-Garcia PIK3C2G M, Bunn PA Jr, Di Maria MV, Veve R, Bremmes RM, Baron AE, Zeng C, Franklin WA: Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003, 21:3798–3807.PubMedCrossRef 5. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497–1500.PubMedCrossRef 6. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, et al.